Citius Oncology, Inc. Increase (Decrease) in Inventories
Citius Oncology, Inc. (CTOR) reported Increase (Decrease) in Inventories of $339.25 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-14
- Citius Oncology, Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$33.65K, a 101.80% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was $20.25K, a 97.89% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was $352.65K, a 94.23% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was $3.71M.
- Citius Oncology, Inc. increase (decrease) in inventories for fiscal 2025 was $12.65M, a 492.78% increase from fiscal 2024.
- Citius Oncology, Inc. increase (decrease) in inventories for fiscal 2024 was $2.13M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$33.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | -$13.40K derived: sum of 2 quarters · filed 2026-08-14 | $339.25K 10-Q · filed 2026-08-14 | $4.05M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $20.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $372.90K 10-Q · filed 2026-05-15 | $4.08M derived: sum of 3 quarters · filed 2026-05-15 | $5.95M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $352.65K 10-Q · filed 2026-02-13 | $4.06M derived: sum of 2 quarters · filed 2026-02-13 | $5.93M derived: sum of 3 quarters · filed 2026-08-14 | $6.89M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $5.58M derived: sum of 2 quarters · filed 2026-08-14 | $6.54M derived: sum of 3 quarters · filed 2026-08-14 | $12.65M 10-K · filed 2025-12-23 |
| 2025-06-30 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $2.83M derived: sum of 2 quarters · filed 2026-08-14 | $8.94M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $957.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $7.07M 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | $6.11M 10-Q · filed 2026-02-13 | |||
| 2024-09-30 | $2.13M 10-K · filed 2025-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |